New targeted therapies for gastric cancer

Bibliography

• Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today 2010;40:295-300
   PubMed Web of Science ®Google Scholar
• Al-Batran S, Ho-mann N, Hartmann JT, 5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO), 2010. ASCO Annual Meeting; 2010
   Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;20:2129-39
   Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Lin W, Kao HW, Robinson D, Tyrosine kinases and gastric cancer. Oncogene 2000;19:5680-9
   PubMed Web of Science ®Google Scholar
• Asaoka Y, Tada M, Ikenoue T, Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun 2010;394:1042-6
   PubMed Web of Science ®Google Scholar
• Hynes NE,. Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
   PubMed Web of Science ®Google Scholar
• Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-52
   PubMed Web of Science ®Google Scholar
• Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998;1:31-50
   PubMedGoogle Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Fukushige S, Matsubara K, Yoshida M, Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-8
   PubMed Web of Science ®Google Scholar
• Lee JW, Soung YH, Seo SH, Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12:57-61
   PubMed Web of Science ®Google Scholar
• Cameron DA, Stein S. Drug Insight: intracellular inhibitors of HER2 – clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 2008;5:512-20
   PubMedGoogle Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27
   PubMed Web of Science ®Google Scholar
• Dean M, Park M, Le Beau MM, The human met oncogene is related to the tyrosine kinase oncogenes. Nature 1985;318:385-8
   PubMed Web of Science ®Google Scholar
• Dean M, Park M, Vande Woude GF. Characterization of the rearranged tpr-met oncogene breakpoint. Mol Cell Biol 1987;7:921-4
   PubMed Web of Science ®Google Scholar
• Giordano S, Ponzetto C, Di Renzo MF, Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989;339:155-6
   PubMed Web of Science ®Google Scholar
• Soman NR, Correa P, Ruiz BA, Wogan GN. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA 1991;88:4892-6
   PubMed Web of Science ®Google Scholar
• Wu CW, Li AF, Chi CW, Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 1998;5:817-22
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Yonemura Y, Nojima N, The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 1998;82:2112-22
   PubMed Web of Science ®Google Scholar
• Park WS, Oh RR, Kim YS, Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. Apmis 2000;108:195-200
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4
   PubMed Web of Science ®Google Scholar
• Tada M, Kanai F, Tanaka Y, Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer. Cancer Sci 2010;101:1261-9
   PubMed Web of Science ®Google Scholar
• Churin Y, Al-Ghoul L, Kepp O, Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 2003;161:249-55
   PubMed Web of Science ®Google Scholar
• Bonaventure J, El Ghouzzi V. Molecular and cellular bases of syndromic craniosynostoses. Expert Rev Mol Med 2003;5:1-17
   Google Scholar
• Dutt A, Salvesen HB, Chen TH, Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008;105:8713-17
   PubMed Web of Science ®Google Scholar
• Katoh M, Hattori Y, Sasaki H, K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase. Proc Natl Acad Sci USA 1992;89:2960-4
   PubMed Web of Science ®Google Scholar
• Yoshida T, Sakamoto H, Terada M. Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 1993;4:33-40
   PubMed Web of Science ®Google Scholar
• Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74
   PubMed Web of Science ®Google Scholar
• Yoshida K, Tsuda T, Matsumura T, Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1989;57:285-90
   PubMedGoogle Scholar
• Sugiyama K, Yonemura Y, Miyazaki I. Immunohistochemical study of epidermal growth factor and epidermal growth factor receptor in gastric carcinoma. Cancer 1989;63:1557-61
   PubMed Web of Science ®Google Scholar
• Bennett C, Paterson IM, Corbishley CM, Luqmani YA. Expression of growth factor and epidermal growth factor receptor encoded transcripts in human gastric tissues. Cancer Res 1989;49:2104-11
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Barone C, Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009;101:1261-8
   PubMed Web of Science ®Google Scholar
• Okines AF, Ashley S, Chau I, Epirubicin, oxaliplatin, and capecitabine +/- panitumumab for advanced oesophagogastric (OG) cancer: Dose-finding study for the prospective multicenter randomized phase II/III REAL3 trial. 2010 Gastrointestinal Cancers Symposium; 2010
   Google Scholar
• Wanebo HJ, Safran H, Suntharalingam M, Cetuximab-based neoadjuvant chemoradiation and surgical resection in patients with locally advanced esophageal and gastric cancer. 2009 Gastrointestinal Cancers Symposium; 2009
   Google Scholar
• Guo A, Villen J, Kornhauser J, Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008;105:692-7
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118:2609-19
   PubMed Web of Science ®Google Scholar
• Moutinho C, Mateus AR, Milanezi F, Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008;8:10
   PubMedGoogle Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6
   PubMed Web of Science ®Google Scholar
• Kang Y, Ohtsu A, Van Cutsem E, AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). 2010 ASCO Annual Meeting; 2010
   Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62
   PubMed Web of Science ®Google Scholar
• Parsons DW, Wang TL, Samuels Y, Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science 1997;275:1943-7
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62
   PubMed Web of Science ®Google Scholar
• Byun DS, Cho K, Ryu BK, Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 2003;104:318-27
   PubMed Web of Science ®Google Scholar
• Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82:285-91
   PubMed Web of Science ®Google Scholar
• Sato K, Tamura G, Tsuchiya T, Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virchows Arch 2002;440:160-5
   PubMed Web of Science ®Google Scholar
• Albert S, Serova M, Dreyer C, New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010;19:919-30
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Calne RY, Collier DS, Lim S, Rapamycin for immunosuppression in organ allografting. Lancet 1989;2:227
   PubMed Web of Science ®Google Scholar
• Takiuchi H, Doi T, Muro K, Everolimus in patients with previously treated metastatic gastric cancer: final results of a multicenter phase II study. 2010 Gastrointestinal Cancers Symposium; 2010
   Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27
   PubMed Web of Science ®Google Scholar
• Lu CH, Wyszomierski SL, Tseng LM, Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-8
   PubMed Web of Science ®Google Scholar
• Andre F, Campone M, O'Regan R, Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010;28:5110-5
   Google Scholar
• Young A, Lyons J, Miller AL, Ras signaling and therapies. Adv Cancer Res 2009;102:1-17
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002;1:599-606
   PubMed Web of Science ®Google Scholar
• Bos JL, Verlaan-de Vries M, Marshall CJ, A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. Nucleic Acids Res 1986;14:1209-17
   PubMed Web of Science ®Google Scholar
• Wittinghofer A, Scheffzek K, Ahmadian MR. The interaction of Ras with GTPase-activating proteins. FEBS Lett 1997;410:63-7
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-55
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Iglehart JD, Silver DP. Synthetic lethality – a new direction in cancer-drug development. N Engl J Med 2009;361:189-91
   PubMed Web of Science ®Google Scholar
• Scholl C, Frohling S, Dunn IF, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-34
   PubMed Web of Science ®Google Scholar
• Luo J, Emanuele MJ, Li D, A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12
   PubMed Web of Science ®Google Scholar
• Seto M, Ohta M, Ikenoue T, Reduced expression of RAS protein activator like-1 in gastric cancer. Int J Cancer 2011;128:1293-302
   Google Scholar
• Lee SH, Lee JW, Soung YH, BRAF and KRAS mutations in stomach cancer. Oncogene 2003;22:6942-5
   PubMed Web of Science ®Google Scholar
• Palanisamy N, Ateeq B, Kalyana-Sundaram S, Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010;16:793-8
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9
   PubMed Web of Science ®Google Scholar
• Horii A, Nakatsuru S, Miyoshi Y, The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 1992;52:3231-3
   PubMed Web of Science ®Google Scholar
• Nakatsuru S, Yanagisawa A, Ichii S, Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum Mol Genet 1992;1:559-63
   PubMed Web of Science ®Google Scholar
• Park WS, Oh RR, Park JY, Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999;59:4257-60
   PubMed Web of Science ®Google Scholar
• Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98
   PubMed Web of Science ®Google Scholar
• Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014
   PubMed Web of Science ®Google Scholar
• Taylor MD, Liu L, Raffel C, Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-10
   PubMed Web of Science ®Google Scholar
• Xie J, Murone M, Luoh SM, Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90-2
   PubMed Web of Science ®Google Scholar
• Taipale J, Chen JK, Cooper MK, Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005-9
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J, Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361:1173-8
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, LoRusso PM, Rudin CM, Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72
   PubMed Web of Science ®Google Scholar
• Ohta M, Tateishi K, Kanai F, p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res 2005;65:10822-9
   PubMed Web of Science ®Google Scholar
• Seto M, Ohta M, Asaoka Y, Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. Mol Carcinog 2009;48:703-12
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Miyake T, Matsunaga T, Recent results of therapy for scirrhous gastric cancer. Surg Today 2009;39:290-4
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• Sasako M, Inoue M, Lin JT, Gastric cancer working group report. Jpn J Clin Oncol 2010;40(Suppl 1):i28-37
   PubMedGoogle Scholar
• Koizumi W, Narahara H, Hara T, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21
   PubMed Web of Science ®Google Scholar
• Chen Y, Takita J, Choi YL, Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-4
   PubMed Web of Science ®Google Scholar
• Leary RJ, Lin JC, Cummins J, Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 2008;105:16224-9
   PubMed Web of Science ®Google Scholar
• Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010;11:685-96
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
   PubMed Web of Science ®Google Scholar
• Forbes SA, Bindal N, Bamford S, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39(Database issue):D945-50
   Google Scholar